Robyn E O'hehir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4066385/publications.pdf

Version: 2024-02-01

284 papers 15,038 citations

63 h-index 109 g-index

310 all docs

310 docs citations

310 times ranked

11566 citing authors

#	Article	IF	CITATIONS
1	COVIDâ€19 vaccinesâ€"The way forward. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 15-16.	5.7	3
2	Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1263-1273.	5.7	18
3	Allergen-Specific Immunotherapy. , 2022, , 111-122.		O
4	Development and validation of combined symptomâ€medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
5	Peanut oral immunotherapy: current trends in clinical trials. Immunotherapy Advances, 2022, 2, .	3.0	5
6	Update about Oralair \hat{A}^{\circledast} as a treatment for grass pollen allergic rhinitis. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	2
7	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
8	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
9	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5 . 7	57
10	Novel basophil activation test in the diagnosis of povidone anaphylaxis. Annals of Allergy, Asthma and Immunology, 2021, 126, 98-99.	1.0	2
11	Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency. Cellular and Molecular Immunology, 2021, 18, 588-603.	10.5	17
12	Effects of Extraction Buffer on the Solubility and Immunoreactivity of the Pacific Oyster Allergens. Foods, 2021, 10, 409.	4.3	22
13	Evaluation of Diagnosis and Management of Omega-5-Gliadin Allergy: A Retrospective Survey. Journal of Asthma and Allergy, 2021, Volume 14, 397-403.	3.4	2
14	Differentiation of COVIDâ€19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€EAAClâ€GA ² LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
15	CytoBas: Precision componentâ€resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3028-3040.	5.7	8
16	Vaccines and allergic reactions: The past, the current COVIDâ€19 pandemic, and future perspectives. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1640-1660.	5.7	72
17	Advances in allergenâ€specific immune cell measurements for improved detection of allergic sensitization and immunotherapy responses. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3374-3382.	5.7	10
18	Management of anaphylaxis due to COVIDâ€19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	5.7	16

#	Article	IF	CITATIONS
19	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
20	Identifying an effective mobile health application for the self-management of allergic rhinitis and asthma in Australia. Journal of Asthma, 2020, 57, 1128-1139.	1.7	27
21	Induction of IgG ₂ and IgG ₄ Bâ€cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1121-1132.	5.7	56
22	Stateâ€ofâ€theâ€art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 746-760.	5.7	42
23	Thunderstorm asthma: an overview of mechanisms and management strategies. Expert Review of Clinical Immunology, 2020, 16, 1005-1017.	3.0	6
24	Influenzaâ€specific IgG1 ⁺ memory Bâ€eell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency. Clinical and Translational Immunology, 2020, 9, e1199.	3.8	12
25	Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3039-3068.	5.7	127
26	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	11.9	244
27	A compendium answering 150 questions on COVIDâ€19 and SARSâ€CoVâ€2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	5.7	95
28	Collagenâ€"An Important Fish Allergen for Improved Diagnosis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3084-3092.e10.	3.8	26
29	Paradoxical Vocal Fold Motion in Difficult Asthma Is Associated with Dysfunctional Breathing and Preserved Lung Function. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2256-2262.	3.8	14
30	Systematic Assessment for Difficult and Severe Asthma Improves Outcomes and Halves Oral Corticosteroid Burden Independent of Monoclonal Biologic Use. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1616-1624.	3.8	25
31	Epidemic thunderstorm asthma susceptibility from sensitization to ryegrass (<i>Lolium perenne</i>) pollen and major allergen Lol p 5. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2369-2372.	5.7	21
32	Effect of structural stability on endolysosomal degradation and Tâ€eell reactivity of major shrimp allergen tropomyosin. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2909-2919.	5.7	25
33	Hypotensive episodes associated with azithromycin infusion: a potentially fatal adverse drug reaction. Respirology Case Reports, 2019, 7, e00464.	0.6	4
34	Defining specific allergens for improved component-resolved diagnosis of shrimp allergy in adults. Molecular Immunology, 2019, 112, 330-337.	2.2	12
35	Recent developments and highlights in immune monitoring of allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2342-2354.	5.7	29
36	Factors Associated with Dysfunctional Breathing in Patients with Difficult to Treat Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1471-1476.	3.8	35

#	Article	IF	Citations
37	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2293-2311.	5.7	76
38	Impaired STAT3-Dependent Upregulation of IL2RÎ \pm in B Cells of a Patient With a STAT1 Gain-of-Function Mutation. Frontiers in Immunology, 2019, 10, 768.	4.8	9
39	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology, 2019, 144, 135-143.e6.	2.9	101
40	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	3.2	81
41	<p>Strongyloides infection as a reversible cause of chronic urticaria</p> . Journal of Asthma and Allergy, 2019, Volume 12, 67-69.	3.4	7
42	Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop. Journal of Allergy and Clinical Immunology, 2019, 143, 1711-1726.	2.9	20
43	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5 . 7	140
44	Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1440-1449.	3.8	12
45	Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells. Frontiers in Immunology, 2019, 10, 2593.	4.8	41
46	<scp>ARIA</scp> pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy― Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
47	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	2.9	73
48	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
49	Breathing pattern disorder in difficult asthma: Characteristics and improvement in asthma control and quality of life after breathing reâ€ŧraining. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 201-203.	5.7	16
50	The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admission. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 122-130.	5.7	56
51	Continued loss of asthma control following epidemic thunderstorm asthma. Asia Pacific Allergy, 2019, 9, e35.	1.3	5
52	Epidemic Thunderstorm Asthma Protection with Five-Grass Pollen Tablet Sublingual Immunotherapy: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 126-128.	5.6	38
53	Nonadherence in the era of severe asthma biologics and thermoplasty. European Respiratory Journal, 2018, 51, 1701836.	6.7	85
54	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1622-1631.	5 . 7	69

#	Article	IF	CITATIONS
55	Treatment of allergic rhinitis using mobile technology with realâ€world data: The <scp>MASK</scp> observational pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1763-1774.	5.7	94
56	Rapid and comprehensive discovery of unreported shellfish allergens using large-scale transcriptomic and proteomic resources. Journal of Allergy and Clinical Immunology, 2018, 141, 1501-1504.e8.	2.9	42
57	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp> â€∢scp>ARIA) â€∙ <scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
58	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 505-510.	5.7	77
59	Recent developments and highlights in biomarkers in allergic diseases and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2290-2305.	5.7	77
60	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clinical and Translational Allergy, 2018, 8, 45.	3.2	104
61	Effect of Heat Processing on IgE Reactivity and Crossâ€Reactivity of Tropomyosin and Other Allergens of Asiaâ€Pacific Mollusc Species: Identification of Novel Sydney Rock Oyster Tropomyosin Sac g 1. Molecular Nutrition and Food Research, 2018, 62, e1800148.	3.3	28
62	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 42-44.	1.3	37
63	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
64	Delayed Diagnosis and Complications of Predominantly Antibody Deficiencies in a Cohort of Australian Adults. Frontiers in Immunology, 2018, 9, 694.	4.8	50
65	Electronic Clinical Decision Support System for allergic rhinitis management: MASK e DSS. Clinical and Experimental Allergy, 2018, 48, 1640-1653.	2.9	61
66	The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planetary Health, The, 2018, 2, e255-e263.	11.4	169
67	Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology, 2017, 140, 486-496.	2.9	52
68	A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 956-964.e3.	3.8	56
69	Work productivity in rhinitis using cell phones: The <scp>MASK</scp> pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	5.7	69
70	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€"2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
71	Assessment of thunderstorm-induced asthma using Google Trends. Journal of Allergy and Clinical Immunology, 2017, 140, 891-893.e7.	2.9	28
72	The Melbourne thunderstorm asthma event: can we avert another strike?. Internal Medicine Journal, 2017, 47, 485-487.	0.8	15

#	Article	IF	Citations
7 3	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <scp>EUFOREA</scp> â€ <scp>ARIA</scp> â€ <scp>EPOS</scp> â€ <scp>AlRWAYS ICP</scp> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	5.7	130
74	OSA is a Key Comorbidity in the Difficult Asthma Cohort. Chest, 2017, 152, A10.	0.8	0
75	Validation of the <scp>MASK</scp> â€rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clinical and Experimental Allergy, 2017, 47, 1526-1533.	2.9	75
76	Activin Biology After Lung Transplantation. Transplantation Direct, 2017, 3, e159.	1.6	5
77	Who's at risk of thunderstorm asthma? The ryegrass pollen trifecta and lessons learnt from the Melbourne thunderstorm epidemic. Respiratory Medicine, 2017, 132, 146-148.	2.9	50
78	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRAIL report. Clinical and Translational Allergy, 2017, 7, 37.	3.2	36
79	Synthetic Nanoparticles That Promote Tumor Necrosis Factor Receptor 2 Expressing Regulatory T Cells in the Lung and Resistance to Allergic Airways Inflammation. Frontiers in Immunology, 2017, 8, 1812.	4.8	13
80	Effect of thermal processing on T cell reactivity of shellfish allergens - Discordance with IgE reactivity. PLoS ONE, 2017, 12, e0173549.	2.5	23
81	Peanut Allergy. , 2016, , 327-341.		0
82	Airline policies for passengers with nut allergies flying from Melbourne Airport. Medical Journal of Australia, 2016, 205, 270-270.	1.7	2
83	Need for intensive care in patients admitted for asthma: Red flags from the social history. Respirology, 2016, 21, 1251-1254.	2.3	13
84	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
85	Elevation in Activin A to Follistatin Ratios Following Lung Transplantation- A Potential Mediator and Therapeutic Target for CLAD?. Journal of Heart and Lung Transplantation, 2016, 35, S177.	0.6	0
86	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
87	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	6.7	50
88	Egg provoked food proteinâ€induced enterocolitisâ€like syndrome in an adult. Clinical Case Reports (discontinued), 2016, 4, 899-901.	0.5	14
89	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47
90	Editorial overview: Allergy and hypersensitivity. Current Opinion in Immunology, 2016, 42, v-vii.	5.5	0

#	Article	IF	Citations
91	Elevated total serum immunoglobulin E (>1000 <scp>IU</scp> / <scp>mL</scp>): implications?. Internal Medicine Journal, 2016, 46, 846-849.	0.8	12
92	Coexisting atopic conditions influence the likelihood of allergic bronchopulmonary aspergillosis in asthma. Annals of Allergy, Asthma and Immunology, 2016, 117, 29-32.e1.	1.0	11
93	International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. Journal of Allergy and Clinical Immunology, 2016, 137, 358-368.	2.9	199
94	T Cell Epitope Peptide Therapy for Allergic Diseases. Current Allergy and Asthma Reports, 2016, 16, 14.	5.3	49
95	Anaphylaxis to oats after cutaneous sensitization byÂoatmeal in skin products used for the treatment of atopic dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 152-153.	3.8	12
96	Substantial Increases Occur in Serum Activins and Follistatin during Lung Transplantation. PLoS ONE, 2016, 11, e0140948.	2.5	5
97	High Fat Diet Inhibits Dendritic Cell and T Cell Response to Allergens but Does Not Impair Inhalational Respiratory Tolerance. PLoS ONE, 2016, 11, e0160407.	2.5	22
98	Persistent Treatment Effect with Grass Synthetic Peptide Immuno-Regulatory Epitopes in Grass Allergy Symptoms in an Environmental Exposure Unit Challenge after a Second Season of Natural Pollen Exposure. Journal of Allergy and Clinical Immunology, 2015, 135, AB158.	2.9	10
99	Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clinical and Experimental Allergy, 2015, 45, 1015-1026.	2.9	81
100	The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clinical and Experimental Allergy, 2015, 45, 1510-1522.	2.9	35
101	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	5.7	160
102	The Editor takes a closer look at some of this month's articles. Clinical and Experimental Allergy, 2015, 45, 1720-1720.	2.9	0
103	Current developments for improving efficacy of allergy vaccines. Expert Review of Vaccines, 2015, 14, 1073-1087.	4.4	19
104	Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 192-199.	3.8	138
105	International consensus on allergy immunotherapy. Journal of Allergy and Clinical Immunology, 2015, 136, 556-568.	2.9	427
106	The activin A antagonist follistatin inhibits cystic fibrosisâ€like lung inflammation and pathology. Immunology and Cell Biology, 2015, 93, 567-574.	2.3	28
107	The innate response to peanut extract in ovine afferent lymph and its correlation with allergen sensitisation. Immunology and Cell Biology, 2015, 93, 533-539.	2.3	2
108	A randomized, placebo-controlled trial using anti-lgE to treat allergic bronchopulmonary aspergillosis. , $2015, \ldots$		0

#	Article	IF	CITATIONS
109	Auto-induction for high yield expression of recombinant novel isoallergen tropomyosin from King prawn (Melicertus latisulcatus) for improved diagnostics and immunotherapeutics. Journal of Immunological Methods, 2014, 415, 6-16.	1.4	19
110	The effects of engineered nanoparticles on pulmonary immune homeostasis. Drug Metabolism Reviews, 2014, 46, 176-190.	3.6	41
111	Effect of heat processing on antibody reactivity to allergen variants and fragments of black tiger prawn: A comprehensive allergenomic approach. Molecular Nutrition and Food Research, 2014, 58, 1144-1155.	3.3	92
112	Goat's cheese anaphylaxis after cutaneous sensitization by moisturizer that contained goat's milk. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 629-630.	3.8	15
113	Differential IgE binding to isoallergens from Asian seabass (Lates calcarifer) in children and adults. Molecular Immunology, 2014, 62, 77-85.	2.2	23
114	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	6.7	154
115	Tolerogenic Dendritic Cells Derived from Donors with Natural Rubber Latex Allergy Modulate Allergen-Specific T-Cell Responses and IgE Production. PLoS ONE, 2014, 9, e85930.	2.5	22
116	Allergic Bronchopulmonary Aspergillosis and Hypersensitivity Pneumonitis., 2014,, 1000-1013.		3
117	Sublingual Immunotherapy for Inhalant Allergens. , 2014, , 1438-1446.		1
118	Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints. Journal of Immunology, 2013, 191, 5278-5290.	0.8	83
119	Ara h 1 CD4+ T cell epitopeâ€based peptides: candidates for a peanut allergy therapeutic. Clinical and Experimental Allergy, 2013, 43, 684-697.	2.9	63
120	Peripheral lung function in patients with stable and unstable asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 1322-1328.	2.9	72
121	Tolerance to wheat in whole-grain cereal biscuit in wheat-allergic children. Journal of Allergy and Clinical Immunology, 2013, 131, 920-923.	2.9	9
122	Intractable shellfish anaphylaxis: sensitization by cross-reactive substances in a complementary "immune stimulant―and acrylic nails. Annals of Allergy, Asthma and Immunology, 2013, 110, 211-212.	1.0	2
123	Novel Use of Rituximab in a Case of Riedel's Thyroiditis Refractory to Glucocorticoids and Tamoxifen. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3543-3549.	3.6	35
124	The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax, 2013, 68, 9-18.	5. 6	43
125	Use of Animal Models to Investigate Major Allergens Associated with Food Allergy. Journal of Allergy, 2013, 2013, 1-10.	0.7	30
126	<scp>TLR</scp> ligands of ryegrass pollen microbial contaminants enhance <scp>T</scp> h1 and <scp>T</scp> h2 responses and decrease induction of <scp>F</scp> oxp3 ^{hi} regulatory <scp>T</scp> cells. European Journal of Immunology, 2013, 43, 723-733.	2.9	15

#	Article	IF	Citations
127	IgE Reactivity of Blue Swimmer Crab (Portunus pelagicus) Tropomyosin, Por p 1, and Other Allergens; Cross-Reactivity with Black Tiger Prawn and Effects of Heating. PLoS ONE, 2013, 8, e67487.	2.5	65
128	MHC Class II Expression in Human Basophils: Induction and Lack of Functional Significance. PLoS ONE, 2013, 8, e81777.	2.5	28
129	T Cell Targeted Strategies for Improved Efficacy and Safety of Specific Immunotherapy for Allergic Disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 201-222.	1.1	7
130	Anaphylaxis - identification, management and prevention. Australian Family Physician, 2013, 42, 38-42.	0.5	5
131	Unique and Cross-Reactive T Cell Epitope Peptides of the Major Bahia Grass Pollen Allergen, Pas n 1. International Archives of Allergy and Immunology, 2012, 159, 355-366.	2.1	28
132	Inert 50-nm Polystyrene Nanoparticles That Modify Pulmonary Dendritic Cell Function and Inhibit Allergic Airway Inflammation. Journal of Immunology, 2012, 188, 1431-1441.	0.8	51
133	An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential. Clinical and Experimental Allergy, 2012, 42, 1801-1812.	2.9	32
134	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	2.9	486
135	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA ² LEN – ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	2.1	83
136	Galectin-10, a Potential Biomarker of Eosinophilic Airway Inflammation. PLoS ONE, 2012, 7, e42549.	2.5	51
137	Impact of helminth infection on childhood allergic diseases in an area in transition from high to low infection burden. Asia Pacific Allergy, 2012, 2, 122-128.	1.3	16
138	Practical guide to skin prick tests in allergy to aeroallergens. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 18-24.	5.7	475
139	Changing of the guard. Histopathology, 2012, 60, 233-235.	2.9	3
140	The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Molecular and Cellular Endocrinology, 2012, 359, 101-106.	3.2	139
141	Special issue on severe asthma. Clinical and Experimental Allergy, 2012, 42, 611-611.	2.9	2
142	Induction of Allergic Responses to Peanut Allergen in Sheep. PLoS ONE, 2012, 7, e51386.	2.5	9
143	ACEI associated angioedema. Australian Family Physician, 2012, 41, 89; author reply 89.	0.5	0
144	Ara h 2 peptides containing dominant CD4+ T-cell epitopes: Candidates for a peanut allergy therapeutic. Journal of Allergy and Clinical Immunology, 2011, 127, 608-615.e5.	2.9	83

#	Article	IF	CITATIONS
145	Anaphylaxis to apple and orange seed. Journal of Allergy and Clinical Immunology, 2011, 128, 1363-1365.	2.9	20
146	A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabiei. Diagnostic Microbiology and Infectious Disease, 2011, 71, 403-407.	1.8	52
147	Functional immunoglobulin E crossâ€reactivity between Pas n 1 of Bahia grass pollen and other group 1 grass pollen allergens. Clinical and Experimental Allergy, 2011, 41, 281-291.	2.9	29
148	The evolution of oral immunotherapy for the treatment of peanut allergy. Clinical and Experimental Allergy, 2011, 41, 1172-1174.	2.9	10
149	The dominant 55kDa allergen of the subtropical Bahia grass (Paspalum notatum) pollen is a group 13 pollen allergen, Pas n 13. Molecular Immunology, 2011, 48, 931-940.	2.2	15
150	Transition from common to private coasts: Consequences of privatization of the coastal commons. Ocean and Coastal Management, 2011, 54, 66-74.	4.4	53
151	Clinical Allergy to Hazelnut and Peanut: Identification of T Cell Cross-Reactive Allergens. International Archives of Allergy and Immunology, 2011, 155, 345-354.	2.1	20
152	Purification of the Major Group 1 Allergen from Bahia Grass Pollen, Pas n 1. International Archives of Allergy and Immunology, 2011, 154, 295-298.	2.1	13
153	Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 926-927.	5.7	56
154	Functional regulatory T cells and allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 559-566.	2.3	43
155	Characterization and <i>de novo</i> sequencing of snow crab tropomyosin enzymatic peptides by both electrospary ionization and matrixâ€assisted laser desorption ionization QqToF tandem mass spectrometry. Journal of Mass Spectrometry, 2010, 45, 372-381.	1.6	26
156	Shellfish allergy. Clinical and Experimental Allergy, 2010, 40, 850-858.	2.9	211
157	Development and implementation of guidelines in allergic rhinitis – an ARIAâ€GA ² LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	5.7	85
158	Immunotherapy in asthma. Immunotherapy, 2010, 2, 711-725.	2.0	7
159	Increased Allergic Immune Response to <i>Sarcoptes scabiei</i> Antigens in Crusted versus Ordinary Scabies. Vaccine Journal, 2010, 17, 1428-1438.	3.1	81
160	The Effector T Cell Response to Ryegrass Pollen Is Counterregulated by Simultaneous Induction of Regulatory T Cells. Journal of Immunology, 2010, 184, 4708-4716.	0.8	23
161	Interleukin-13 Regulates Secretion of the Tumor Growth Factor–β Superfamily Cytokine Activin A in Allergic Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 667-675.	2.9	27
162	Improving general practice consultations for older people with asthma: a cluster randomised control trial. Medical Journal of Australia, 2009, 191, 113-117.	1.7	8

#	Article	IF	Citations
163	House Dust Mite Sublingual Immunotherapy. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 936-947.	5.6	158
164	Allergen-related approaches to immunotherapy. , 2009, 121, 273-284.		72
165	Treating allergy: where to from here?. Internal Medicine Journal, 2009, 39, 491-494.	0.8	0
166	Subâ€lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
167	Sub-Lingual Immunotherapy. World Allergy Organization Journal, 2009, 2, 233-281.	3.5	100
168	Allergic rhinitis and its impact on asthma update (ARIA 2008)—western and Asian-Pacific perspective. Asian Pacific Journal of Allergy and Immunology, 2009, 27, 237-43.	0.4	19
169	Experience with a new commercial skin testing kit to identify IgE-mediated penicillin allergy. Internal Medicine Journal, 2008, 38, 357-361.	0.8	12
170	Immunogenetic characteristics of immunoglobulin E in allergic disease. Clinical and Experimental Allergy, 2008, 38, 566-578.	2.9	20
171	Latex allergy: a model for therapy. Clinical and Experimental Allergy, 2008, 38, 898-912.	2.9	58
172	Molecular cloning, expression and immunological characterisation of Pas n 1, the major allergen of Bahia grass Paspalum notatum pollen. Molecular Immunology, 2008, 46, 286-293.	2.2	25
173	Specific and Sensitive Enzyme-Linked Immunosorbent Assays for Analysis of Residual Allergenic Food Proteins in Commercial Bottled Wine Fined with Egg White, Milk, and Nongrape-Derived Tannins. Journal of Agricultural and Food Chemistry, 2008, 56, 349-354.	5.2	51
174	Sublingual Allergen Immunotherapy: Immunological Mechanisms and Prospects for Refined Vaccine Preparations. Current Medicinal Chemistry, 2007, 14, 2235-2244.	2.4	27
175	IgE cross-reactivity between the major peanut allergen Ara h 2 and tree nut allergens. Molecular Immunology, 2007, 44, 463-471.	2.2	84
176	Risk-minimisation strategies for peanut allergy. Lancet, The, 2007, 370, 483.	13.7	3
177	Anaphylaxis to lemon soap: citrus seed and peanut allergen cross-reactivity. Annals of Allergy, Asthma and Immunology, 2007, 98, 286-289.	1.0	28
178	The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy. Expert Reviews in Molecular Medicine, 2007, 9, 1-18.	3.9	61
179	What's in a kiss: Peanut allergen transmission as a sensitizer?. Journal of Allergy and Clinical Immunology, 2007, 119, 755.	2.9	9
180	â€`You have to learn to live with it': a qualitative and quantitative study of older people with asthma. Clinical Respiratory Journal, 2007, 1, 99-105.	1.6	25

#	Article	IF	CITATIONS
181	1. Diagnosis, treatment and prevention of allergic disease: the basics. Medical Journal of Australia, 2006, 185, 228-233.	1.7	51
182	Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma. Clinical and Experimental Allergy, 2006, 36, 941-950.	2.9	49
183	Anaphylaxis to Gelofusine $\langle \sup \hat{A}^{\otimes} \langle \sup \rangle$ confirmed by $\langle i \rangle$ in vitro $\langle i \rangle$ basophil activation test: a case series*. Anaesthesia, 2006, 61, 264-268.	3.8	51
184	ADAM33 haplotypes are associated with asthma in a large Australian population. European Journal of Human Genetics, 2006, 14, 1027-1036.	2.8	58
185	Potential food allergens in wine: Double-blind, placebo-controlled trial and basophil activation analysis. Nutrition, 2006, 22, 882-888.	2.4	48
186	Advances in development of hypoallergenic latex immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 544-551.	2.3	11
187	Characterization of the Tâ€cell epitopes of a major peanut allergen, Ara h 2. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 35-40.	5.7	57
188	Bahia grass pollen specific IgE is common in seasonal rhinitis patients but has limited crossâ€reactivity with Ryegrass. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 251-255.	5.7	35
189	Functional analysis of crossâ€reactive immunoglobulin E antibodies: peanutâ€specific immunoglobulin E sensitizes basophils to tree nut allergens. Clinical and Experimental Allergy, 2005, 35, 1056-1064.	2.9	47
190	Transgenic ryegrasses (Lolium spp.) with down-regulation of main pollen allergens. Molecular Breeding, 2005, 14, 489-501.	2.1	10
191	The Latex Allergen Hev b 5 Is an Antigen with Repetitive Murine B-Cell Epitopes. International Archives of Allergy and Immunology, 2004, 134, 334-340.	2.1	9
192	High Dose Allergen Stimulation of T Cells from House Dust Mite-Allergic Subjects Induces Expansion of IFN- \hat{l}^3 + T Cells, Apoptosis of CD4+IL-4+ T Cells and T Cell Anergy. International Archives of Allergy and Immunology, 2004, 133, 1-13.	2.1	37
193	Hypoallergenic Variants of the Major Latex Allergen Hev b 6.01 Retaining Human T Lymphocyte Reactivity. Journal of Immunology, 2004, 173, 5872-5879.	0.8	76
194	Increased allergen concentration enhances IFN-gamma production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1308-1317.	5.7	21
195	VH gene usage in immunoglobulin E responses of seasonal rhinitis patients allergic to grass pollen is oligoclonal and antigen driven. Clinical and Experimental Allergy, 2004, 34, 429-436.	2.9	32
196	Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clinical and Experimental Allergy, 2004, 34, 1209-1219.	2.9	87
197	The hevein domain of the major latex-glove allergen Hev b 6.01 contains dominant T cell reactive sites. Clinical and Experimental Allergy, 2004, 34, 611-618.	2.9	23
198	Blocking antibodies in allergen immunotherapy: the Yin and Yang. Clinical and Experimental Allergy, 2004, 34, 510-512.	2.9	16

#	Article	IF	CITATIONS
199	Transgenic ryegrasses (Lolium spp.) with down-regulation of main pollen allergens. Molecular Breeding, 2004, 14, 489-501.	2.1	31
200	Molecular Cloning and Characterization of Hazel Pollen Protein (70 kD) as a Luminal Binding Protein (BiP): A Novel Cross-Reactive Plant Allergen. International Archives of Allergy and Immunology, 2003, 131, 91-100.	2.1	32
201	Emergency treatment of asthma: how are we doing?. Internal Medicine Journal, 2003, 33, 401-403.	0.8	2
202	Role of intravenous immunoglobulin in severe steroidâ€dependent asthma. Internal Medicine Journal, 2003, 33, 341-344.	0.8	20
203	Immunological analysis of allergenic crossâ€reactivity between peanut and tree nuts. Clinical and Experimental Allergy, 2003, 33, 1273-1280.	2.9	121
204	Consensus group on newâ€generation antihistamines (CONGA): present status and recommendations. Clinical and Experimental Allergy, 2003, 33, 1305-1324.	2.9	161
205	Characterization of a Mouse Model of Allergy to a Major Occupational Latex Glove Allergen Hev b 5. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1393-1399.	5.6	26
206	Adrenaline and non-life threatening allergic reactions: Intramuscular adrenaline is safe. BMJ: British Medical Journal, 2003, 327, 226-c-227.	2.3	11
207	T Cell Targeted Allergen Derivatives for Improved Efficacy and Safety of Specific Immunotherapy for Allergic Disease. Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents, 2003, 2, 351-365.	0.4	1
208	Oligoclonal Analysis of the Atopic T Cell Response to the Group 1 Allergen of <i>Cynodon dactylon</i> (Bermuda Grass) Pollen: Pre- and Post-Allergen-Specific Immunotherapy. International Archives of Allergy and Immunology, 2002, 127, 234-244.	2.1	38
209	Hev b 5 double mutant proteins. Journal of Allergy and Clinical Immunology, 2002, 109, S133-S133.	2.9	0
210	Interventions of latex allergen inhaled by health care workers through use of breathing masks or non-powdered gloves. Journal of Allergy and Clinical Immunology, 2002, 109, S257-S257.	2.9	1
211	Immunology and allergy. Medical Journal of Australia, 2002, 176, 22-22.	1.7	0
212	Characterization of the human T cell response to rye grass pollen allergens Lol p 1 and Lol p 5. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 1136-1144.	5.7	22
213	Specific allergen immunotherapy: time for alternatives?. Clinical and Experimental Allergy, 2002, 32, 1-3.	2.9	20
214	Specific monoclonal antibodies and human immunoglobulin E show that Hev b 5 is an abundant allergen in high protein powdered latex gloves. Clinical and Experimental Allergy, 2002, 32, 583-589.	2.9	33
215	Particulate masks and nonâ€powdered gloves reduce latex allergen inhaled by healthcare workers. Clinical and Experimental Allergy, 2002, 32, 1166-1169.	2.9	20
216	Latex allergy: towards immunotherapy for health care workers. Clinical and Experimental Allergy, 2002, 32, 667-673.	2.9	9

#	Article	IF	CITATIONS
217	Allergen immunotherapy: Current and new therapeutic strategies. Allergology International, 2002, 51, 221-231.	3.3	3
218	A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction. FEBS Letters, 2001, 502, 46-52.	2.8	21
219	Adverse events associated with rush Hymenoptera venom immunotherapy. Medical Journal of Australia, 2001, 174, 227-230.	1.7	16
220	Chlorhexidine anaphylaxis: a case report and review of the literature. Internal Medicine Journal, 2001, 31, 436-437.	0.8	33
221	A rapid and efficient two-step gel electrophoresis method for the purification of major rye grass pollen allergens. Electrophoresis, 2001, 22, 1900-1905.	2.4	7
222	What Determines Asthma Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S211-S214.	5.6	21
223	Allergen immunotherapy: current and new therapeutic strategies. Expert Opinion on Investigational Drugs, 2000, 9, 515-527.	4.1	36
224	Human T-cell epitopes of the latex allergen Hev b 5 in health care workers. Journal of Allergy and Clinical Immunology, 2000, 105, 1017-1024.	2.9	36
225	Use of phage display technology to investigate allergen-antibody interactions. Journal of Allergy and Clinical Immunology, 2000, 105, 1085-1092.	2.9	24
226	556 Macadamia nut anaphylaxis: Demonstrations of specific IgE reactivity and partial cross reactivity with Hazelnut. Journal of Allergy and Clinical Immunology, 2000, 105, S184.	2.9	1
227	713 Human T cell epitopes of the latex allergen Hev b 5 in health care workers. Journal of Allergy and Clinical Immunology, 2000, 105, S241.	2.9	1
228	851 Molecular cloning and immunological characterization of Lol p 5C, a novel allergen isoform of rye grass pollen demonstrating high IgE reactivity. Journal of Allergy and Clinical Immunology, 2000, 105, S290.	2.9	0
229	Stinging insect allergy. Medical Journal of Australia, 1999, 171, 649-650.	1.7	7
230	Murine B-cell and T-cell epitopes of the allergen Hev b 5 from natural rubber latex. Molecular Immunology, 1999, 36, 135-143.	2.2	21
231	Molecular cloning, expression and immunological characterisation of Lol p 5C, a novel allergen isoform of rye grass pollen demonstrating high lgE reactivity ¹ . FEBS Letters, 1999, 462, 435-441.	2.8	13
232	Macadamia nut anaphylaxis: Demonstration of specific IgE reactivity and partial cross-reactivity with hazelnut. Journal of Allergy and Clinical Immunology, 1999, 104, 889-890.	2.9	44
233	T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope. Journal of Allergy and Clinical Immunology, 1999, 103, 255-261.	2.9	15
234	Immunotherapy of allergy: anergy, deletion, and immune deviation. Current Opinion in Immunology, 1998, 10, 640-645.	5.5	84

#	Article	IF	Citations
235	Prevalence of severe ant-venom allergy in southeastern Australia. Journal of Allergy and Clinical Immunology, 1998, 101, 129-131.	2.9	38
236	Successful Desensitization of Two Patients Who Previously Developed Stevensâ€Johnson Syndrome While Receiving Trimethoprimâ€Sulfamethoxazole. Clinical Infectious Diseases, 1997, 25, 1480-1480.	5.8	30
237	Desensitization to itraconazole. Journal of Allergy and Clinical Immunology, 1997, 99, 269-269.	2.9	8
238	Prevalence of IgEâ€mediated allergy to latex in hospital nursing staff. Australian and New Zealand Journal of Medicine, 1997, 27, 165-169.	0.5	39
239	T-cell receptor peptides that inhibit the T-cell response to allergen induce transforming growth factor- \hat{l}^2 production. Journal of Allergy and Clinical Immunology, 1996, 97, 707-709.	2.9	6
240	Allergy and asthma in Central Australia. Medical Journal of Australia, 1996, 165, 526-526.	1.7	3
241	Oligoclonal V gene usage by T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients American Journal of Respiratory Cell and Molecular Biology, 1996, 14, 470-477.	2.9	22
242	Reversal of the inhibitory effects of HIVâ€gp120 on CD4 + T cells by stimulation through the CD28 pathway. Clinical and Experimental Immunology, 1996, 105, 225-230.	2.6	11
243	Regulation of cytokine and chemokine transcription in a human TH2 type T-cell clone during the induction phase of anergy. Clinical and Experimental Allergy, 1996, 26, 20-27.	2.9	16
244	Peptide Mediated Regulation of Allergen Specific Immune Responses. Advances in Experimental Medicine and Biology, 1996, , 451-456.	1.6	0
245	Modulation of immune responses to allergens of house dust mite. Biochemical Society Transactions, 1995, 23, 660-664.	3.4	0
246	Clonal analysis of CD4 mediated accessory function on the effector activity of human CD4+ T cell subsets. Clinical and Experimental Allergy, 1995, 25, 839-847.	2.9	2
247	Differential dependence of TH-0, TH-1 and TH-2 CD4 4+ T cells on co-stimulatory activity provided by the accessory molecule LFA-1. Clinical and Experimental Allergy, 1995, 25, 1163-1170.	2.9	5
248	Differential induction of the NF-AT complex during restimulation and the induction of T-cell anergy. Human Immunology, 1995, 42, 95-102.	2.4	17
249	Identification of two binding sites in staphylococcal enterotoxin B that confer specificity for TCR $\hat{Vl^2}$ gene products. International Immunology, 1994, 6, 199-211.	4.0	24
250	Inhibition of human T-cell responses to house dust mite allergens by a T-cell receptor peptide. Journal of Allergy and Clinical Immunology, 1994, 94, 844-852.	2.9	24
251	Overlapping T-cell epitopes in the group I allergen of species restricted by HLA-DP and HLA-DR class II molecules. Journal of Allergy and Clinical Immunology, 1994, 93, 891-899.	2.9	92
252	T CELLS IN HEALTH AND DISEASE. Clinical and Experimental Allergy, 1993, 23, 8-8.	2.9	14

#	Article	IF	CITATIONS
253	House dust mite allergy: from T-cell epitopes to immuno-therapy. European Journal of Clinical Investigation, 1993, 23, 763-772.	3.4	48
254	Analysis of human T cell responses to the group II allergen of Dermatophagoides species: Localization of major antigenic sites. Journal of Allergy and Clinical Immunology, 1993, 92, 105-113.	2.9	89
255	CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. International Immunology, 1993, 5, 461-466.	4.0	49
256	Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp.: identification of HLA-DR and -DQ restricted T cell epitopes. International Immunology, 1993, 5, 1589-1597.	4.0	78
257	Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice Journal of Experimental Medicine, 1993, 178, 1783-1788.	8.5	327
258	In vivo clonal dominance and limited T-cell receptor usage in human CD4+ T-cell recognition of house dust mite allergens Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8214-8218.	7.1	94
259	Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor Journal of Experimental Medicine, 1992, 175, 1493-1499.	8.5	142
260	Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with spp. (house dust) Tj ETQq0	0 <u>9 rg</u> BT /(Overlock 10 T
261	What can we learn from studies of lymphocytes present in allergic-reaction sites?. Journal of Allergy and Clinical Immunology, 1992, 89, 783-788.	2.9	16
262	Strategies for modulating immunoglobulin E synthesis. Clinical and Experimental Allergy, 1992, 22, 7-10.	2.9	6
263	Staphylococcus aureus enterotoxin mediated specific non-responsiveness of human T cells. Immunology Letters, 1991, 30, 165-170.	2.5	5
264	Contribution of T-cell receptor-contacting and peptide-binding residues of the class II molecule HLA-DR4 Dw10 to serologic and antigen-specific T-cell recognition. Human Immunology, 1991, 32, 110-118.	2.4	29
265	An in vitro model of peptide-mediated immunomodulation of the human T cell response to Dermatophagoides spp (house dust mite). Journal of Allergy and Clinical Immunology, 1991, 87, 1120-1127.	2.9	30
266	The cellular and molecular basis of the human T cell response to Dermatophagoides spp. (house dust) Tj ETQq0 C) 0 ₁ .gBT /C)verlock 10 Tf
267	Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T-cell clones. Clinical and Experimental Allergy, 1991, 21, 209-215.	2.9	38
268	MHC Class II and allergen-specific T cell clones. Clinical and Experimental Allergy, 1991, 21, 173-177.	2.9	3
269	HLA-DR4Dw4-restricted T cell recognition of self antigen(s) in the rheumatoid synovial compartment. International Immunology, 1991, 3, 635-640.	4.0	23
270	The Specificity and Regulation of T-Cell Responsiveness to Allergens. Annual Review of Immunology, 1991, 9, 67-95.	21.8	130

#	Article	IF	Citations
271	Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. International Immunology, 1991, 3, 819-826.	4.0	102
272	Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8884-8888.	7.1	130
273	Direct evidence for a functional role of HLA-DRB1 and-DRB3 gene products in the recognition of Dermatophagoides spp.(house dust mite) by helper T lymphocytes. International Immunology, 1990, 2, 885-892.	4.0	43
274	HLA class II restriction specificity of Dermatophagoides spp. reactive T lymphocyte clones that support IgE synthesis. Clinical and Experimental Allergy, 1989, 19, 389-393.	2.9	8
275	Action of Nedocromil Sodium and Sodium Cromoglycate on Cloned Human Allergen-Specific CD4+ T Lymphocytes. Drugs, 1989, 37, 23-25.	10.9	6
276	T Lymphocytes in Allergen-Induced Late-Phase Reactions and Asthma. International Archives of Allergy and Immunology, 1989, 88, 63-67.	2.1	22
277	Clonal Analysis of the Cellular Immune Response to the House Dust Mite <i>Dermatophagoides farinae</i> . International Archives of Allergy and Immunology, 1989, 88, 170-172.	2.1	4
278	The use of nitrocellulose immunoblots for the analysis of antigen recognition by T lymphocytes. Journal of Immunological Methods, 1988, 110, 1-10.	1.4	60
279	265 Antigen-induced neutrophil chemotactic activity (NCA) derived from cloned human T lymphocytes. Journal of Allergy and Clinical Immunology, 1988, 81, 234.	2.9	0
280	559 Antigen and restriction specificity of human T lymphocyte clones reactive with dermatophagoides farinae (house dust mite). Journal of Allergy and Clinical Immunology, 1988, 81, 308.	2.9	0
281	Acute Myopathy in Severe Acute Asthma Treated with Intravenously Administered Corticosteroids. The American Review of Respiratory Disease, 1988, 137, 460-463.	2.9	113
282	Comparison of the Effects of Nebulized Terbutaline with Intravenous Enprofylline in Patients with Acute Asthma. Chest, 1988, 93, 510-514.	0.8	7
283	Stinging insect allergy. Journal of Allergy and Clinical Immunology, 1986, 77, 649.	2.9	1
284	TWO PATIENTS WITH ABNORMALITIES OF REGIONAL SYMPATHETIC NERVOUS TONE. Australian and New Zealand Journal of Medicine, 1984, 14, 855-859.	0.5	1